Yuliya Velikorodnaya

Yuliya Velikorodnaya

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in Nanotechnologies in Russia
Verified
Journal Article
Closed access
PDF file
YVYuliya Velikorodnaya
Yuliya Velikorodnaya
APA. Ya. Pocheptsov
A. Ya. Pocheptsov
OSO. I. Sokolov
O. I. Sokolov
VBV. A. Bogatyrev
V. A. Bogatyrev
LDL. A. Dykman
L. A. Dykman
In the present study we investigate the effect of 5-nm gold nanoparticles on the proliferation and apoptosis of spermatogenesis in rats. It is found that the per os administration of gold nanoparticle

11 January 2023 in Molecules
Verified
Journal Article
Open access
PDF file
Alexander SpasovAlexander Spasov
Alexander Spasov
IOIrina Ovchinnikova
Irina Ovchinnikova
OFOlga Fedorova
Olga Fedorova
YTYulia Titova
Yulia Titova
Denis BabkovDenis Babkov
Denis Babkov
Valery N. CharushinValery N. Charushin
Valery N. Charushin
The problem of lung damage originating from excessive inflammation and cytokine release during various types of infections remains relevant and stimulates the search for highly effective and safe drugs. The biological activity of the latter may be associated with the regulation of hyperactivation of certain immune cells and enzymes. Here, we propose the design and synthesis of amino derivatives of 4,6- and 5,7-diaryl substituted pyrimidines and [1,2,4]triazolo[1,5-a]pyrimidines as promising double-acting pharmacophores inhibiting IL-6 and NO. The anti-inflammatory activity of 14 target compounds was studied on isolated primary murine macrophages after LPS stimulation. Seven compounds were identified to inhibit the synthesis of nitric oxide and interleukin 6 at a concentration of 100 µM. The most active compounds are micromolar inhibitors of IL-6 secretion and NO synthesis, showing a minimal impact on innate immunity, unlike the reference drug dexamethasone, along with acceptable cytotoxicity. Evaluation in an animal model of acute lung injury proved the protective activity of compound 6e, which was supported by biochemical, cytological and morphological markers.

27 April 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Alexander SpasovAlexander Spasov
Alexander Spasov
VKVadim Kosolapov
Vadim Kosolapov
Denis BabkovDenis Babkov
Denis Babkov
VKVladlen Klochkov
Vladlen Klochkov
ESElena Sokolova
Elena Sokolova
VRVladimir Rusinov
Vladimir Rusinov
Acute lung injury remains a challenging clinical condition, necessitating the development of novel, safe and efficient treatments. The prevention of macrophage M1-polarization is a viable venue to tackle excessive inflammation. We performed a phenotypic screening campaign to identify azolopyrimidine compounds that effectively inhibit LPS-induced NO synthesis and interleukin 6 (IL-6) secretion. We identified lead compound 9g that inhibits IL-6 secretion with IC50 of 3.72 µM without apparent cytotoxicity and with minimal suppression of macrophage phagocytosis in contrast to dexamethasone. In a mouse model of LPS-induced acute lung injury, 30 mg/kg i.p. 9g ameliorated anxiety-like behavior, inhibited IL-6 release, and limited neutrophil infiltration and pulmonary edema. A histological study confirmed the protective activity of 9g. Treatment with compound 9g prevented the migration of CD68+ macrophages and the incidence of hemorrhage. Hence, we have identified a promising pharmacological approach for the treatment of acute lung injury that may hold promise for the development of novel drugs against cytokine-mediated complications of bacterial and viral infections.

20 November 2023 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
ITI Tyurenkov
I Tyurenkov
DBDmitry Bakulin
Dmitry Bakulin
ASA Smirnov
A Smirnov
MEM Ekova
M Ekova
ABA Bisinbekova
A Bisinbekova
OVO Vasilyeva
O Vasilyeva
The aimof the workwas to evaluate the GABA neuroprotective properties and its structural analogues in old animals after seven months of hyperglycemia.Materials and methods.Diabetes mellitus was modeled in white outbred male rats (12 months old) by the administration of a streptozotocin (65 mg/kg) and nicotinamide (230 mg/kg) combination. After 6 months, the animals with a postprandial glycemia level between 11 and 18 mmol/l were selected for the study. After the groups had been formed, the animals were administrated with GABA and GABAergic compounds (Compositions МРВАand PPC), respectively, for 1 month, the control group animals were administrated with saline. After the treatment, an oral glucose tolerance test and a set of behavioral tests aimed at studying sensory-motor (Open Field, Adhesion test, Rotarod) and cognitive functions (New Object Recognition and Morris Water Maze), as well as the functional state evaluation of the endothelium were performed. Further on, sampling of blood and brain tissues for a biochemical and enzyme immunoassay (the level of glucagon-like peptide-1 (GLP-1) and TNF-α in serum and the level of Klotho protein, BDNF, Nrf2, NF-κB and malondialdehyd (MDA) in brain homogenates), as well as a morphological analysis of changes in CA1 and CA3 neurons of the hippocampus and somatosensory cortex, was carried out.Results.GABA and compositions with its derivatives had a pronounced neuroprotective effect in old animals with prolonged hyperglycemia. The hypoglycemic effect of the studied compositions was accompanied by an increase in the production of GLP-1. In the animals with DM, after 6 weeks of the test substances administration, higher rates of sensory-motor and cognitive functions and a less structural damage to the sensory-motor cortex and the brain hippocampus were recorded. These effects may be due to higher levels of the Klotho proteins, Nrf2 and BDNF, as well as lower levels of NF-κB, which may underlie the suppression of the oxidative stress, the reduction of MDA and inflammation (TNF-α).Conclusion.After 6 weeks of the administration, GABA and its compositions in old animals (19 months old) significantly improved sensory-motor and cognitive functions, reduced negative structural changes in the hippocampus and somatosensory cerebral cortex.

20 October 2022 in Life
Verified
Journal Article
Open access
PDF file
Alexander SpasovAlexander Spasov
Alexander Spasov
AOAlexander Ozerov
Alexander Ozerov
VKVadim Kosolapov
Vadim Kosolapov
NGNatalia Gurova
Natalia Gurova
AKAida Kucheryavenko
Aida Kucheryavenko
YVYuliya Velikorodnaya
Yuliya Velikorodnaya
Quinazolines are a rich source of bioactive compounds. Previously, we showed NHE-1 inhibitory, anti-inflammatory, antiplatelet, intraocular pressure lowering, and antiglycating activity for a series of quinazoline-2,4(1H,3H)-diones and quinazoline-4(3H)-one guanidine derivatives. In the present work, novel N1,N3-bis-substituted quinazoline-2,4(1H,3H)-dione derivatives bearing two guanidine moieties were synthesized and pharmacologically profiled. The most potent NHE-1 inhibitor 3a also possesses antiplatelet and intraocular-pressure-reducing activity. Compound 4a inhibits NO synthesis and IL-6 secretion in murine macrophages without immunotoxicity and alleviates neutrophil infiltration, edema, and tissue lesions in a model of LPS-induced acute lung injury. Hence, we considered quinazoline derivative 4a as a potential agent for suppression of cytokine-mediated inflammatory response and acute lung injury.

1 May 2016 in Doklady Biochemistry and Biophysics
Verified
Journal Article
Closed access
OSO. I. Sokolov
O. I. Sokolov
NSN. Y. Selivanov
N. Y. Selivanov
VBV. A. Bogatyrev
V. A. Bogatyrev
OSO. G. Selivanova
O. G. Selivanova
YVYuliya Velikorodnaya
Yuliya Velikorodnaya
LDL. A. Dykman
L. A. Dykman
The aim of this research was to design a method of immobilization of high-purity human butyrylcholinesterase on the surface of gold nanoparticles preserving the activity of the enzyme. In order to achieve this aim, the method of fractionation and purification of human butyrylcholinesterase from plasma was modified. The synthesis of 15-nm gold nanoparticles was carried out by citrated method. A method of conjugation of the high-purity butyrylcholinesterase with gold nanoparticles was developed. It was found that the Immobilization of butyrylcholinesterase on the surface of gold nanoparticles resulted in a significant (to 23%) increase in the specific activity of the enzyme.